ClinicalTrials.gg
RecruitingNCT06655701Updated Dec 12, 2024

Stress Urinary Incontinence and Sarcopenia in Postmenopausal Osteoporosis

An observational study in Osteoporosis, Postmenopausal, sponsored by Beylikduzu State Hospital. Recruiting at 1 site in Turkey. Open to female participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-12.

Sponsored by Beylikduzu State Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
100
Ages
50 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Osteoporosis, Postmenopausal with a site in Turkey — 4 open to participants now, 5 under way, none of them phase 3. Osteoporosis, Postmenopausal · Turkey.

Started
2024
with 1 other
Observational
9 of 20
2 open now
Registered
14th of 20
by date
Lead sponsor
1 of 20
Beylikduzu State Hospital

Among the 20 studies in Osteoporosis, Postmenopausal with a site in Turkey, this one is one of 2 that started in 2024, is one of 9 observational ones, and was the 14th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

4 of the 20 studies in Osteoporosis, Postmenopausal with a site in Turkey are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 50 Years to 75 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Osteoporosis, Postmenopausal with a site in Turkey, or all of them as a file.
02

Study summary

The primary aim of our study is to evaluate the presence of stress urinary incontinence in postmenopausal patients with and without osteoporosis, determine its impact on quality of life, and explore its relationship with sarcopenia.

Read the detailed description

One hundred postmenopausal women, aged 50-75, who applied to the Physical Therapy and Rehabilitation outpatient clinic at Beylikdüzü State Hospital and have Dual-X-ray Absorptiometry (DXA) measurements taken within the last 6 months, including both osteoporotic and non-osteoporotic patients, will be included in the study. Sociodemographic data such as age, gender, height, weight, and BMI will be recorded. DXA results, including femoral neck and L1-L4 T-scores and BMD values, will be obtained. Patients will be asked about osteoporosis treatment, presence of fecal incontinence, constipation, and medication use. Stress urinary incontinence will be determined through a questionnaire, and its impact on quality of life will be assessed using the Incontinence Quality of Life Scale. In the second phase, sarcopenia will be evaluated according to the Asian Working Group for Sarcopenia (AWGS) criteria by assessing skeletal muscle mass (via bioelectrical impedance analysis), handgrip strength, and the 5-times sit-to-stand test.

03

Conditions studied

  • Osteoporosis, Postmenopausal
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Postmenopausal women

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women with DXA measurements performed within the last 6 months.
  • Based on DXA measurements:

Femoral neck and L1-L4 T-scores of -1 and above will be included in the control group (non-osteoporotic).

Femoral neck and L1-L4 T-scores of -2.5 and below will be included in the osteoporosis group.

  • Aged 50-75 years

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate in the study.
  • History of neurological diseases, infections, surgeries, or trauma that could cause urinary incontinence or muscle loss.
  • Presence of psychiatric disorders.
  • Cognitive impairments.
  • Use of medications that could affect the study results.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Postmenopausal osteoporosis

    Postmenopausal osteoporosis is diagnosed using Dual-X-ray Absorptiometry (DXA), which measures bone mineral density (BMD) and provides a T-score. A T-score of -2.5 or lower confirms the diagnosis of osteoporosis.

    Diagnostic Test: No intervention

  • Postmenopausal non-osteoporotic women

    These women maintain normal bone mineral density (BMD) levels, typically assessed using Dual-X-ray Absorptiometry (DXA). A T-score above -1.0 is considered normal.

    Diagnostic Test: No intervention

Interventions

  • Diagnostic testNo intervention

    No intervention

06

What researchers measure

Primary outcomes

  1. Presence of Stress Urinary Incontinence:

    Stress urinary incontinence (SUI) is the involuntary leakage of urine during physical activities that increase abdominal pressure, such as coughing, sneezing, or lifting. In this study, the presence of SUI will be determined through a questionnaire that asks participants about symptoms and frequency of urine leakage during such activities.

    Time frame: 0 day

  2. Incontinence Quality of Life Scale (I-QOL):

    The I-QOL is a validated questionnaire that measures the impact of urinary incontinence on a patient's quality of life. It assesses how incontinence affects daily activities, social interactions, and emotional well-being. Higher scores indicate better quality of life, while lower scores suggest that incontinence has a more significant negative impact on the patient's day-to-day functioning.

    Time frame: 0 day

  3. Skeletal Muscle Mass:

    Measured by bioelectrical impedance analysis (BIA), this assesses the amount of muscle tissue in the body. Low skeletal muscle mass indicates sarcopenia.

    Time frame: 0 day

  4. Handgrip Strength

    This is a simple test to measure muscle strength. Reduced handgrip strength is a sign of sarcopenia.

    Time frame: 0 day

07

Study locations

1 of 1 sites recruiting
  • Beylikdüzü State Hospital
    Istanbul, 34147, Turkey
    Recruiting
    • Büşra Şirin Ahısha, MD · Contactbsrn080@gmail.com · (0212) 856 27 40
    • Büşra Şirin Ahısha, MD · Principal investigator
    • Fatma Nur Kesiktaş, Prof · Sub investigator
    • Nurdan Paker, Prof · Sub investigator
    • Nazlı Derya Buğdaycı, Doc · Sub investigator
    • Yiğit Can Ahısha, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Jan 2025, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2024
First posted
Oct 23, 2024
StartActual
Nov 15, 2024
Primary completionEst.
Jan 15, 2025
CompletionEst.
Jan 15, 2025
Last update
Dec 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06655701
Lead sponsor
Beylikduzu State Hospital
Responsible party
Busra Sirin (Principle Investigator, Beylikduzu State Hospital) — Principal investigator
First posted
Oct 23, 2024
Start date
Nov 15, 2024
Primary completion
Jan 15, 2025 (estimated)
Completion
Jan 15, 2025 (estimated)
Last update
Dec 12, 2024

Study contacts

Büşra Şirin Ahısha, MD
Contact
bsrn080@gmail.com
(0212) 856 27 40

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion